UK-SBA Speakers’ Series 8 with Prof Jesse Dallery

Dates: 9-10 November 2017

BACB CEUs: 5.5 on 9 Nov and 6 on 10 Nov (Type 2, includes 3 ethics CEUs on 10 Nov; included in registration fee)
Venue: University College London, 26 Bedford Way, WC1H 0AP

Please note: Thursday’s (9 Nov) event begins at 11:30; Friday’s 10 (Nov) event begins at 9:30 (see timetables below)

Jesse Dallery is a Professor in the Department of Psychology at the University of Florida, a Licensed Psychologist in the state of Florida, and Deputy Director of the Treatment Development and Evaluation Core at the Center for Technology and Behavioral Health at Dartmouth.  Jesse received his Ph.D. in Clinical Psychology from Emory University, and completed a postdoctoral fellowship at the Johns Hopkins University School of Medicine in Behavioral Pharmacology.  Jesse’s research focuses on integrating information technologies with behavioral interventions for cigarette smoking and other health-related behavior (e.g., physical activity, medication adherence).  Jesse also conducts translational research on choice, decision making, and relapse in the human laboratory, with a special emphasis on quantitative models of operant behavior.  He has published over seventy articles in peer-reviewed journals, and he has received grant support from the National Institutes of Health and from the National Science Foundation. Jesse is a former Associate Editor for The Behavior Analyst and Behavioural Processes, and former Special Topics Associate Editor (substance abuse) for the Journal of Applied Behavior Analysis.


Day 1 (Thursday, 9 November)

Part 1: Understanding Substance Misuse and Treatment: An Operant Approach

Dr. Dallery will trace the roots of an operant view of drug use, and contrast this view with alternative models.  Research using animal models will be discussed, in particular their role in clarifying relevant variables and processes that influence drug self-administration.  The operant view led to powerful, novel treatments for drug use and related disorders.  At their core, these treatments provide alternative, non-drug reinforcers for evidence of behavior change.  Dr. Dallery will describe the origins of these interventions, including critical, science-based components that influence their efficacy.  He will also highlight research on voucher-based contingency management.


  • Describe an operant perspective on drug use and how this view contrasts with traditional models of drug use.
  • State the core features of contingency management interventions that influence their efficacy in clinical settings.
  • Describe the procedure and results of at least one study that used voucher-based contingency management to promote drug abstinence.

Part 2: Best Practice in Contingency Management Interventions for High-Risk Populations

The success of contingency management interventions led to a range of innovative extensions.  One issue in contingency management has been cost.  Prize-based contingency management and deposit contracts can lower cost while retaining efficacy.  Another issue is long-term behavior change.  The therapeutic workplace was designed to employ high risk groups, in which admission to the workplace is contingent on drug abstinence.  In addition, contingency management has been applied in a variety of high-risk groups.  Dr. Dallery will focus on adolescents, individuals with HIV, and pregnant women, including some recent large-scale, population-based interventions.  Finally, he will discuss some portable, clinical procedures and recommendations that may be used in a generic and broadly applicable manner.


  • Describe the advantages and outcomes associated with prize-based contingency management.
  • Describe the therapeutic workplace, including how it has been used to address some of the most intractable problems in urban environments.
  • Describe at least two procedures or recommendations relevant to clinical use of contingency management.

Day 2 (Friday, 10 November)

Part 1: Contingency Management through Technology: Practical and Ethical Considerations

Information technology permeates our everyday lives.  Until recently, it has been relatively neglected as a medium to deliver contingencies of reinforcement to change behavior.  Dr. Dallery will discuss a variety of methods to harness technology to change problem behavior such as cigarette smoking, alcohol use, physical inactivity, and medication non-adherence.  He will discuss methods to deliver contingency management to promote smoking cessation at the national level and to high-risk groups, reduce the costs associated with treatment, and integrate social consequences to promote and potentially sustain behavior change.  These innovations may address many of the limitations (access, cost, sustainability, dissemination potential) inherent in traditional contingency management delivery models.  Information technology offers unprecedented and rapidly expanding opportunities to measure and promote behavior change.


  • Describe how information technology can be used to obtain objective evidence of the presence or absence of behavior and deliver incentives.
  • Describe how social consequences have been used to promote smoking cessation using information technology.
  • Discuss advantages and challenges associated with the use of technology to promote behavior change

Part 2: Behavior Analysis and the Future of Contingency Management

Although contingency management interventions are effective for many patients, significant challenges remain.  First, more research is needed to improve the effectiveness of these interventions, and to address longer-term relapse following treatment.  Dr. Dallery will discuss how behavioral technology can be harnessed to address these challenges.  Indeed, he will argue that behavior analysts can and should take a leadership role in advancing this science.  Such advances, in combination with education for policy makers, clinicians, and the population at large, can also address challenges associated with dissemination and implementation.  Contingency management interventions are still not widely used in the United States or in the United Kingdom, despite some promising developments.  Nevertheless, there are tremendous opportunities to broaden our reach, and markedly impact public health with contingency management.


  • Discuss some of the gaps in research related to the effects of contingency management.
  • Describe recent efforts to disseminate contingency management.
  • Generate ideas about how behavior analytic technology can be applied to address some of the gaps and limitations associated with contingency management. 


Thursday 9 November   Friday 10 November 
5.5 BACB Type 2 CEUs available6 BACB Type 2 CEUs available
11:30 - 1:30Session 19:30 - 11:30Session 1
1:30 - 2:00Lunch break11:30 - 1:00Lunch Break
2:00 - 3:30Session 21:00 - 3:00Session 2
3:30 - 4:00Break3:00 - 3:30Break
4:00 - 5:30Session 33:30 - 5:30Session 3
  • November 9, 2018 - November 12, 2018
    11:00 am - 5:00 pm
We're sorry, but all tickets sales have ended because the event is expired.